UVA1terapia

UVA1terapia, or UVA1 phototerapia, is a dermatological treatment that uses long-wave ultraviolet A radiation, typically in the 340–400 nanometer range, delivered by calibrated lamps. The procedure is conducted in specialized clinics, with patients wearing protective eyewear and, when appropriate, shielding of sensitive areas. The administered dose is tailored to the individual and increased gradually over a course of treatment.

Indications and clinical use: UVA1 therapy is employed for inflammatory and fibrotic skin conditions. The strongest evidence supports use in morphea (localized scleroderma), where UVA1 can help reduce dermal fibrosis and improve skin pliability. Other conditions, such as certain inflammatory dermatoses including atopic dermatitis, have been treated with UVA1 with variable results. It is generally considered after failure or intolerance of more conventional therapies, and its use depends on disease characteristics, skin type, and clinical judgment.

Administration and regimen: treatment sessions typically involve exposure for a short period several times weekly over several weeks. The dose is gradually increased based on tolerance and clinical response, and the exact protocol varies by device and patient. Protective measures, especially for the eyes, are mandatory, and exposure to UVA1 is avoided in situations of known photosensitivity or active infections in the treatment area.

Safety and limitations: UVA1 penetrates deeper into the dermis than ultraviolet B light, and while it carries a lower risk of immediate sunburn, cumulative exposure can contribute to photoaging and carries theoretical carcinogenic risk with long-term use. Common short-term effects include dryness, mild erythema, and pigment changes. Contraindications include photosensitivity disorders, active skin cancers in the treatment area, porphyria, and certain conditions during pregnancy. Clinical decisions should balance potential benefits against risks.